

# Cibele L Garzillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1773831/publications.pdf>

Version: 2024-02-01

36  
papers

670  
citations

623734

14  
h-index

580821

25  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Follow-Up of a Randomized Comparison Between Off-Pump and On-Pump Stable Multivessel Coronary Artery Bypass Grafting. The MASS III Trial. <i>Circulation</i> , 2010, 122, S48-S52.	1.6	105
2	Intensive care management of patients with COVID-19: a practical approach. <i>Annals of Intensive Care</i> , 2021, 11, 36.	4.6	73
3	Characterization of Reactive Astrocytes in the Chronic Phase of the Pilocarpine Model of Epilepsy. <i>Epilepsia</i> , 2002, 43, 107-109.	5.1	57
4	Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease. <i>Circulation</i> , 2012, 126, S158-63.	1.6	56
5	Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. <i>American Heart Journal</i> , 2013, 166, 250-257.	2.7	54
6	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. <i>Circulation</i> , 2012, 126, S145-50.	1.6	33
7	Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease. <i>Diabetes Care</i> , 2013, 36, 1654-1659.	8.6	29
8	Cancer-related deaths among different treatment options in chronic coronary artery disease. <i>Coronary Artery Disease</i> , 2012, 23, 79-84.	0.7	24
9	Association Between Stress Testingâ€œInduced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1345.	5.1	24
10	Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 1443-1449.	0.8	21
11	Accuracy of Myocardial Biomarkers in the Diagnosis of Myocardial Infarction After Revascularization as Assessed by Cardiac Resonance: The Medicine, Angioplasty, Surgery Study V (MASS-V) Trial. <i>Annals of Thoracic Surgery</i> , 2016, 101, 2202-2208.	1.3	20
12	Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. <i>Cardiovascular Diabetology</i> , 2015, 14, 66.	6.8	17
13	Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. <i>European Heart Journal</i> , 2013, 34, 3370-3377.	2.2	16
14	Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1735-1744.	1.3	16
15	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. <i>JAMA Network Open</i> , 2020, 3, e1919666.	5.9	14
16	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1369-1376.	0.7	13
17	Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. <i>Coronary Artery Disease</i> , 2008, 19, 383-388.	0.7	12
18	Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: Effect of age in the Medicine, Angioplasty, or Surgery Study II trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 1105-1112.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III. <i>Angiology</i> , 2019, 70, 337-344.	1.8	11
20	Custos comparativos entre a revasculariza�o miocrdica com e sem circula�o extracorprea. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 91, 369-376.	0.8	11
21	Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 65.	1.7	10
22	Biomarker release after percutaneous coronary intervention in patients without established myocardial infarction as assessed by cardiac magnetic resonance with late gadolinium enhancement. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 87-93.	1.7	5
23	Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 92.	2.7	5
24	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. <i>International Journal of Cardiology</i> , 2018, 273, 63-68.	1.7	5
25	Hypotheses, rationale, design, and methods for evaluation of ischemic preconditioning assessed by sequential exercise tests in diabetic and non-diabetic patients with stable coronary artery disease – a prospective study. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 117.	1.7	4
26	Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance. <i>Medicine (United Tj ETQq0 0 OrgBT /Overlock 10 TF</i>		
27	Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 122.	1.1	4
28	Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF). <i>Trials</i> , 2020, 21, 337.	1.6	2
29	Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study. <i>Journal of Cardiothoracic Surgery</i> , 2021, 16, 248.	1.1	1
30	Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 47.	1.7	0
31	HIGH NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS PREDICT ENHANCED PERIPROCEDURAL INFLAMMATORY RESPONSE FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN STABLE ISCHEMIC HEART DISEASE PATIENTS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 124.	2.8	0
32	COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP. <i>Journal of the American College of Cardiology</i> , 2017, 69, 100.	2.8	0
33	VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 137.	2.8	0
34	Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease. <i>Coronary Artery Disease</i> , 2019, 30, 536-541.	0.7	0
35	Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Disease – Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 166.	5.1	0
36	Occurrence of recently diagnosed atrial fibrillation in the immediate postoperative period of myocardial revascularization surgery. Although common, a devalued complication. <i>Revista Da Associa�o Mdica Brasileira</i> , 2020, 66, 1473-1475.	0.7	0